$2.45
N/A
Last update: Nov 11, 9:25 AM
Rocket Pharmaceuticals Inc
RCKTNASDAQ
Rocket Pharmaceuticals fell 24.8% from $3.26 to $2.45, behind the S&P 500's +9.8%. Its worst day was Mar 27 (−19.6%), and its low came Oct 16 at $2.18.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.38 beat the $-0.42 estimate on $0.00 revenue (est. $277,780.00).
+10.6% · S&P 500 −0.5%
Rocket Pharmaceuticals closed at its highest level of the year, 62.6% above where the year started.
Story events cover the past 12 months · Times ET
+3.7% · S&P 500 −0.2%
First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections
−19.6%, the year's worst day, on 23M shares, the year's heaviest volume · S&P 500 −1.7%
EPS of $-0.42 beat the $-0.44 estimate on $0.00 revenue.
−1.1% · S&P 500 +0.8%
Rocket Pharmaceuticals shares rose 12.9%, while the S&P 500 fell 1.5%.
+12.9% · S&P 500 −1.5%
EPS of $-0.37 missed the $0.34 estimate on $0.00 revenue (est. $13.3M).
−3.8% · S&P 500 −0.3%
Rocket Pharmaceuticals shares fell 10.9%, while the S&P 500 fell 0.1%.
−10.9% · S&P 500 −0.1%
Rocket Pharmaceuticals closed at its lowest level of the year, 33.1% below where the year started.
−7.6% · S&P 500 −1.1%
Where it ended: a close of $2.45 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.40, revenue est. $445,456.00).
Nothing in the past 12 months.
All RCKT dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RCKT and SPY from Benzinga historical bars. Not investment advice.
